StockData

Axsome Therapeutics vs Harmony Biosciences

AXSM and HRMY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AXSM and HRMY compare

Axsome Therapeutics is the larger company, worth 3.7 times as much as Harmony Biosciences ($7.1B against $1.9B).

Axsome Therapeutics grew revenue faster over the last twelve months (56.9% versus 24.3% for Harmony Biosciences).

Harmony Biosciences keeps more of each dollar of sales as profit, with a net margin of 18.9% compared with −24.7% at Axsome Therapeutics.

Harmony Biosciences scores higher on the StockData Score (18 against 8 for Axsome Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAXSMHRMY
Size and price
Market cap$7.1B$1.9B
Share price$135.95$33.01
Change, 1 year−2.7%−3.0%
Change, 5 years268%−12.1%
Beta (5Y)0.871.11
Employees500293
StockData Score
Total score818 (better)
Valuation score06 (better)
Growth score3 (better)2
Performance score24 (better)
Health score36 (better)
Dividend score00
Valuation
P/E–10.7×
P/S9.2×2.0× (better)
P/B85.5×1.9× (better)
EV/EBITDA–6.1×
FCF yield−1.0%–
Fair value–$53.99
Margin of safety–38.9%
Growth
Revenue growth (TTM)56.9% (better)24.3%
Revenue growth, 5Y average–40.3%
Net income growth (TTM)–0.20%
EPS growth (TTM)–−0.32%
Profitability
Gross margin93.2% (better)75.4%
Operating margin−24.0%24.0% (better)
Net margin−24.7%18.9% (better)
FCF margin−9.3%–
Return on equity−245%20.5% (better)
Return on invested capital–40.1%
Financial health
Debt / equity2.260.15 (better)
Net debt / EBITDA–−2.23
Interest coverage–17.1×
Current ratio1.433.48 (better)
Altman Z-score4.215.12 (better)
Piotroski F-score55
Dividends and buybacks
Buyback yield−0.50%–
Shareholder yield−0.50%0.00% (better)
Ownership
Held by institutions73.8%93.0%
Held by insiders15.2%12.1%
Insider net buying, 12 months−$113M−$5.8M (better)
Short interest, % of float7.3%13.0%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.